应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06887 东阳光药
未开盘 11-17 16:08:15
36.500
+0.000
0.00%
最高
37.120
最低
36.020
成交量
14.83万
今开
36.500
昨收
36.500
日振幅
3.01%
总市值
209.51亿
流通市值
116.44亿
总股本
5.74亿
成交额
539.84万
换手率
0.05%
流通股本
3.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
非执行董事张寓帅增持东阳光药(06887)7万股 每股作价约36.62港元
智通财经网 · 11-17 19:19
非执行董事张寓帅增持东阳光药(06887)7万股 每股作价约36.62港元
东阳光药:张寓帅增持,好仓比例升至40.62%
港股披露 · 11-17 17:31
东阳光药:张寓帅增持,好仓比例升至40.62%
东阳光药(06887):奥洛格列净胶囊成功纳入2026版国家医保药品目录
智通财经 · 11-15 18:41
东阳光药(06887):奥洛格列净胶囊成功纳入2026版国家医保药品目录
东阳光药(06887.HK):自主创新药奥洛格列淨胶囊进入2026版国家医保目录
公告速递 · 11-15 18:32
东阳光药(06887.HK):自主创新药奥洛格列淨胶囊进入2026版国家医保目录
东阳光药1类降糖新药奥洛格列净纳入国家医保目录
经济参考网 · 11-14
东阳光药1类降糖新药奥洛格列净纳入国家医保目录
东阳光药奥洛格列净胶囊纳入国家医保药品目录
格隆汇 · 11-14
东阳光药奥洛格列净胶囊纳入国家医保药品目录
非执行董事张寓帅三日增持东阳光药(06887.HK)25.66万股 耗资约990.45万港元
智通财经 · 11-12
非执行董事张寓帅三日增持东阳光药(06887.HK)25.66万股 耗资约990.45万港元
东阳光药:张寓帅增持,好仓比例升至40.6%
港股披露 · 11-12
东阳光药:张寓帅增持,好仓比例升至40.6%
东阳光药:张寓帅增持,好仓比例升至40.56%
港股披露 · 11-11
东阳光药:张寓帅增持,好仓比例升至40.56%
东阳光药:张寓帅增持,好仓比例升至40.52%
港股披露 · 11-10
东阳光药:张寓帅增持,好仓比例升至40.52%
东阳光药:张寓帅增持,好仓比例升至40.53%
港股披露 · 11-10
东阳光药:张寓帅增持,好仓比例升至40.53%
张寓帅增持东阳光药(06887)10.90万股 每股作价38.99港元
智通财经 · 11-06
张寓帅增持东阳光药(06887)10.90万股 每股作价38.99港元
东阳光药:张寓帅增持,好仓比例升至40.51%
港股披露 · 11-06
东阳光药:张寓帅增持,好仓比例升至40.51%
东阳光药:张寓帅增持,好仓比例升至40.47%
港股披露 · 11-06
东阳光药:张寓帅增持,好仓比例升至40.47%
东阳光药更新10月股份变动月报表,股本维持稳定
公告速递 · 11-04
东阳光药更新10月股份变动月报表,股本维持稳定
东阳光药(06887):区泳娴获委任为公司秘书、授权代表及法律程序代理人
智通财经网 · 10-30
东阳光药(06887):区泳娴获委任为公司秘书、授权代表及法律程序代理人
东阳光药(06887)调整高管:郑程杰辞任公司秘书,区泳嫻接任
公告速递 · 10-30
东阳光药(06887)调整高管:郑程杰辞任公司秘书,区泳嫻接任
国产第二家!东阳光药德谷门冬双胰岛素获批上市
格隆汇 · 10-08
国产第二家!东阳光药德谷门冬双胰岛素获批上市
东阳光药(06887.HK):德谷门冬双胰岛素注射液获得中国国家药品监督管理局的上市批准
智通财经 · 10-08
东阳光药(06887.HK):德谷门冬双胰岛素注射液获得中国国家药品监督管理局的上市批准
东阳光药:张寓帅增持,好仓比例升至40.41%
港股披露 · 10-07
东阳光药:张寓帅增持,好仓比例升至40.41%
加载更多
公司概况
公司名称:
东阳光药
所属市场:
SEHK
上市日期:
--
主营业务:
广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药,亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威(磷酸奥司他韦),用于治疗流行性感冒(特别是甲型及乙型流行性感冒病毒),东卫恩(磷酸依米他韦),用于治疗丙型肝炎,及主要用于治疗敏感细菌引起的感染的仿制药,即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病,包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。
发行价格:
--
{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":36.5,"timestamp":1794902895008,"preClose":36.5,"halted":0,"volume":148291,"delay":0,"changeRate":0,"floatShares":319000000,"shares":574000000,"eps":0.55,"marketStatus":"未开盘","change":0,"latestTime":"11-17 16:08:15","open":36.5,"high":37.12,"low":36.02,"amount":5398389,"amplitude":0.030137,"askPrice":36.5,"askSize":5300,"bidPrice":36.06,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-0.596326247,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794965400000},"marketStatusCode":0,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":36.5,"openAndCloseTimeList":[[1794879000000,1794888000000],[1794891600000,1794902400000]],"volumeRatio":0.3711177301912387,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887","defaultTab":"news","newsList":[{"id":"2684600895","title":"非执行董事张寓帅增持东阳光药(06887)7万股 每股作价约36.62港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2684600895","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684600895?lang=zh_cn&edition=full","pubTime":"2026-11-17 19:19","pubTimestamp":1794914351,"startTime":"0","endTime":"0","summary":"11月13日,非执行董事张寓帅增持东阳光药(06887)7万股,每股作价36.6213港元,总金额约为256.35万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20261117/20261117191946_71133.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20261117/20261117191946_71133.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142047831","title":"东阳光药:张寓帅增持,好仓比例升至40.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142047831","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142047831?lang=zh_cn&edition=full","pubTime":"2026-11-17 17:31","pubTimestamp":1794907902,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月13日在联交所场内以每股均价36.6213港元买入东阳光药(06887)股份7.00万股,涉资约256.35万港元,属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.6%;增持后持股量为1.30亿,好仓比例升至40.62%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683659673","title":"东阳光药(06887):奥洛格列净胶囊成功纳入2026版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683659673","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683659673?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:41","pubTimestamp":1794739308,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药 公布,近日,该集团自主研发的钠-葡萄糖转运蛋白2抑制剂、1类创新药奥洛格列净胶囊被成功纳入中国国家医疗保障局公布的最新版《国家基本医疗保险、生育保险和工伤保险药品目录》。2026版国家医保药品目录将于2027年1月1日起正式执行。该产品于2026年1月获得中国国家药品监督管理局的上市批准,可单药或联合二甲双胍用于改善成人2型糖尿病患者的血糖控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134539950","title":"东阳光药(06887.HK):自主创新药奥洛格列淨胶囊进入2026版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=1134539950","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134539950?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:32","pubTimestamp":1794738752,"startTime":"0","endTime":"0","summary":"2026年11月15日,东阳光药发布自愿性公告称,集团自主研发的钠-葡萄糖转运蛋白2抑制剂1类创新药——奥洛格列淨胶囊,已被纳入国家医疗保障局公布的《国家基本医疗保险、生育保险和工伤保险药品目录》。该目录自2027年1月1日起正式执行。东阳光药表示,将以此次奥洛格列淨胶囊进入医保目录为契机,进一步提升产品可及性,完善糖尿病综合治疗方案,持续推进国内外市场拓展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683297680","title":"东阳光药1类降糖新药奥洛格列净纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683297680","media":"经济参考网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683297680?lang=zh_cn&edition=full","pubTime":"2026-11-14 15:42","pubTimestamp":1794642152,"startTime":"0","endTime":"0","summary":"11月14日,国家医保局正式公布2026年国家医保药品目录及商保创新药目录。东阳光药(06887.HK)自主研发的1类创新降糖药奥洛格列净胶囊(商品名:东泽安?)成功纳入本次医保目录。奥洛格列净是“十三五”国家科技重大专项支持品种,也是国产拥有完全自主知识产权、可适度抑制SGLT-1的SGLT-2抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611143931339049.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611143931339049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683868735","title":"东阳光药奥洛格列净胶囊纳入国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683868735","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683868735?lang=zh_cn&edition=full","pubTime":"2026-11-14 12:44","pubTimestamp":1794631457,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682056762","title":"非执行董事张寓帅三日增持东阳光药(06887.HK)25.66万股 耗资约990.45万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682056762","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682056762?lang=zh_cn&edition=full","pubTime":"2026-11-12 18:57","pubTimestamp":1794481056,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119409192","title":"东阳光药:张寓帅增持,好仓比例升至40.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119409192","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119409192?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:13","pubTimestamp":1794474836,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月11日在联交所场内以每股均价38.47港元买入东阳光药(06887)股份14.00万股,涉资约538.58万港元,属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.56%;增持后持股量为1.30亿,好仓比例升至40.6%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109365176","title":"东阳光药:张寓帅增持,好仓比例升至40.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109365176","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109365176?lang=zh_cn&edition=full","pubTime":"2026-11-11 17:32","pubTimestamp":1794389557,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月10日在联交所场内以每股均价38.78港元买入东阳光药(06887)股份9.00万股,涉资约349.02万港元,属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.53%;增持后持股量为1.30亿,好仓比例升至40.56%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154554638","title":"东阳光药:张寓帅增持,好仓比例升至40.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154554638","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154554638?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:21","pubTimestamp":1794302495,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月6日在联交所场内以每股均价38.74港元买入东阳光药(06887)股份5.00万股,涉资约193.70万港元;该笔属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.51%;增持后持股量为1.30亿,好仓比例升至40.52%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120969227","title":"东阳光药:张寓帅增持,好仓比例升至40.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120969227","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120969227?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:12","pubTimestamp":1794301935,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月9日在联交所场内以每股均价38.6663港元买入东阳光药(06887)股份2.66万股,涉资约102.85万港元;属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.52%;增持后持股量为1.30亿,好仓比例升至40.53%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681863678","title":"张寓帅增持东阳光药(06887)10.90万股 每股作价38.99港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681863678","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681863678?lang=zh_cn&edition=full","pubTime":"2026-11-06 19:35","pubTimestamp":1793964943,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新数据显示,11月5日,张寓帅增持东阳光药(06887)10.9万股,每股作价38.99港元,总金额约为424.99万港元。增持后最新持股数目约为1.30亿股,持股比例为40.51%。补充资料:广东东阳光药业股份有限公司持有2,365,000股库存股份,张寓帅先生被视为于该等库存股份中拥有权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167947317","title":"东阳光药:张寓帅增持,好仓比例升至40.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167947317","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167947317?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:33","pubTimestamp":1793957618,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月5日在联交所场内以每股均价38.99港元买入东阳光药(06887)股份10.90万股,涉资约424.99万港元,属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.47%;增持后持股量为1.30亿,好仓比例升至40.51%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145744054","title":"东阳光药:张寓帅增持,好仓比例升至40.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145744054","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145744054?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:23","pubTimestamp":1793956988,"startTime":"0","endTime":"0","summary":"张寓帅于2026年11月4日在联交所场内以每股均价39.76港元买入东阳光药(06887)股份18.35万股,涉资约729.60万港元,属场内主动交易,即在二级市场直接买卖股份。张寓帅此次增持前持有东阳光药好仓1.30亿,占比40.41%;增持后持股量为1.30亿,好仓比例升至40.47%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191331923","title":"东阳光药更新10月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1191331923","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191331923?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:16","pubTimestamp":1793783784,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年11月4日向香港联合交易所有限公司提交了截至2026年10月31日的股份变动月报表,显示公司本月内未发生注册股本的增减变动,整体股本维持稳定。根据公告,截至本月末,公司法定/注册股本合计为人民币576,656,047元。被购回股份转为库藏股,使得本月末H股流通股数量减少至318,738,140股,库存股数量则为2,365,000股,H股总数维持321,103,140股不变。截至报告期末,公司股本总体保持稳定。本次公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679298439","title":"东阳光药(06887):区泳娴获委任为公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2679298439","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679298439?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:39","pubTimestamp":1793349547,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,郑程杰先生已辞任本公司公司秘书、香港联合交易所有限公司证券上市规则第3.05条规定之本公司授权代表及香港法例第622章公司条例第16部规定之本公司于香港接收法律程序文件及通知之代理人(法律程序代理人),自2026年10月30日起生效。区泳娴女士已获委任为公司秘书、授权代表及法律程序代理人,自2026年10月30日起生效。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127498064","title":"东阳光药(06887)调整高管:郑程杰辞任公司秘书,区泳嫻接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1127498064","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127498064?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:36","pubTimestamp":1793349379,"startTime":"0","endTime":"0","summary":"2026年10月30日,广东东阳光药业股份有限公司发布公告称,公司管理层出现人事变动。郑程杰先生已辞去公司秘书、香港联合交易所有限公司证券上市规则第3.05条所规定的授权代表,以及香港公司条例第16部规定的法律程序代理人职务,辞任自2026年10月30日起生效。郑程杰先生确认,其与董事会并无意见分歧,亦无其他事项需提请股东或联交所注意。同日起,区泳嫻女士被委任接替上述三项职务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673076077","title":"国产第二家!东阳光药德谷门冬双胰岛素获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2673076077","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673076077?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:52","pubTimestamp":1791456775,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673764370","title":"东阳光药(06887.HK):德谷门冬双胰岛素注射液获得中国国家药品监督管理局的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673764370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673764370?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:41","pubTimestamp":1791456062,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130302569","title":"东阳光药:张寓帅增持,好仓比例升至40.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130302569","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130302569?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:22","pubTimestamp":1791364931,"startTime":"0","endTime":"0","summary":"张寓帅于2026年10月2日因广东东阳光药业股份有限公司回购100,700股库存股份(每股均价41.3557港元,涉资416.45万港元),而被视为拥有该等库存股份权益,好仓增加10.07万股。张寓帅此次增持前持有东阳光药好仓1.30亿股,占比40.38%;增持后持股量为1.30亿股,好仓比例升至40.41%。原文链接:Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0598},{"period":"1month","weight":-0.051},{"period":"3month","weight":-0.0188},{"period":"6month","weight":-0.066},{"period":"1year","weight":-0.2393},{"period":"ytd","weight":-0.1996}],"compareEarnings":[{"period":"1week","weight":-0.0427},{"period":"1month","weight":-0.0281},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.074},{"period":"1year","weight":-0.109},{"period":"ytd","weight":-0.0828}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药,亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威(磷酸奥司他韦),用于治疗流行性感冒(特别是甲型及乙型流行性感冒病毒),东卫恩(磷酸依米他韦),用于治疗丙型肝炎,及主要用于治疗敏感细菌引起的感染的仿制药,即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病,包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}